EMA Authorised: Fiasp (insulin aspart) — Novo Nordisk A/S

View source ↗

Summary

European Medicines Agency information indicates that Fiasp (insulin aspart) by Novo Nordisk A/S has been authorised for Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Novo Nordisk A/S. Decision date: 18/08/2021